Retabac Ointment 1% is a topical antibiotic used primarily for the treatment of skin infections. It is a pleuromutilin antibiotic that works by inhibiting bacterial protein synthesis. Retabac Ointment 1% is commonly prescribed for superficial bacterial infections such as impetigo and skin infections caused by specific strains of Staphylococcus aureus and Streptococcus pyogenes.
Retabac Ointment 1% is used for:
| Brand Name | Retabac |
|---|---|
| Type | Ointment |
| Weight | 1% |
| Generic | Retapamulin |
| Manufacturer | Square Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Retabac Ointment 1% works by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit, specifically to the peptidyl transferase center, thereby interfering with the formation of peptide bonds and preventing the growth of bacteria. This action inhibits the synthesis of essential proteins required for bacterial survival and replication.
Retabac Ointment 1% usually begins to show improvement in skin infections within 24 to 48 hours of application. Complete resolution of the infection may take 7 to 10 days, depending on the severity of the infection and adherence to the treatment regimen.
Retabac Ointment 1% is designed for topical use and is minimally absorbed through the skin. Its systemic absorption is negligible, making it effective for localized skin infections with minimal risk of systemic side effects.
Since Retabac Ointment 1% is applied topically and has minimal systemic absorption, there is limited information on its route of elimination. Most of the drug remains localized at the site of application and is eventually removed through normal skin turnover and washing.
The usual dosage for Retabac Ointment 1% is:
Retabac Ointment 1% is administered topically:
Common side effects include:
Systemic toxicity is unlikely due to the minimal absorption of Retabac Ointment 1% through the skin. In cases of overdose or accidental ingestion, supportive care should be provided. Contact a healthcare provider for further guidance if significant adverse effects are observed.
Precautions include:
Drug interactions are unlikely with topical Retabac Ointment 1% due to its minimal systemic absorption. However, it is important to inform the healthcare provider of all medications and topical treatments being used to avoid potential interactions.
Retabac Ointment 1% should be used with caution in individuals with:
Topical Retabac Ointment 1% is unlikely to have significant interactions with systemic drugs due to its minimal systemic absorption. However, combining it with other topical antibiotics should be done with caution and under medical supervision to avoid potential additive effects.
There are no known significant food interactions with Retabac Ointment 1%. It should be applied as directed regardless of food intake.
Retabac Ointment 1% is classified as a Category B drug for pregnancy, indicating that it is generally considered safe for use during pregnancy. However, it should be used only if the potential benefits outweigh the risks. Consult a healthcare provider before use.
The safety of Retabac Ointment 1% during breastfeeding is not well established. Minimal systemic absorption reduces the risk to a breastfeeding infant, but it is advisable to use the drug cautiously and consult a healthcare provider before applying it to areas near the breast.
In case of an acute overdose or excessive application, wash the affected area thoroughly with water. Seek medical advice if unusual symptoms or reactions occur. Systemic toxicity is unlikely due to minimal absorption.
Retabac Ointment 1% is contraindicated in individuals with:
Apply a thin layer of Retabac Ointment 1% ointment to the affected area twice daily. Follow the prescribed duration of use, typically 5 days. Avoid covering the area with occlusive dressings unless instructed by a healthcare provider.
Store Retabac Ointment 1% at room temperature (15°C to 25°C), away from light and moisture. Keep the ointment tightly closed and out of reach of children.
As Retabac Ointment 1% is applied topically, its volume of distribution is localized primarily to the application site with minimal systemic distribution.
The half-life of Retabac Ointment 1% in plasma is not well-defined due to its minimal systemic absorption. The drug remains at the site of application and is gradually eliminated as skin turnover occurs.
The clearance of Retabac Ointment 1% from the application site is primarily through natural skin desquamation and removal, with minimal systemic clearance due to its topical use.
See in details version Retabac Ointment 1% also Retabac Ointment 1% in bangla
Prof. Dr. Sufia Nasrin Rita
Orthodontics (Braces, Bite Problem, Jaw Problem) Specialist & Surgeon